Back to results
US 2014/0371141 A1Published application
Insulin glargine/lixisenatide fixed ratio formulation
OwnerElisabeth Souhami, Louise Silvestreinventors
Life of this patent
Estimating the term…
Abstract
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Claims27
A pharmaceutical composition comprising
- (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and
- (b) insulin glargine or/and a pharmaceutically acceptable salt thereof,
- wherein the compound (b) and compound (a) are present in a ratio of about 1.6 to about 2.4 U of compound (b) per 1 μg of compound (a).
Use of a composition of
- (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and
- (b) insulin glargine or/and a pharmaceutically acceptable salt thereof,
- for the preparation of a composition for the treatment of diabetes mellitus type 1 or/and 2,
- wherein the compound (b) and compound (a) are present in the composition in a ratio of about 1.6 to about 2.4 U of compound (b) per μg of compound (a).
1 more element
A method of treatment of diabetes mellitus type 1 or/and type 2, comprising administering to a subject in need thereof a composition comprising
- (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and
- (b) insulin glargine or/and a pharmaceutically acceptable salt thereof,
- wherein the compound (b) and compound (a) are present in a ratio of about 1.6 to about 2.4 U of compound (b) per μg of compound (a).
Dependencies are inferred from the claim text.